Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

jaguar health inc - JAGX

JAGX

Close Chg Chg %
1.13 -0.04 -3.54%

Closed Market

1.09

-0.04 (3.54%)

Volume: 126.31K

Last Updated:

Dec 26, 2025, 4:00 PM EDT

Trade Now

Company Overview: jaguar health inc - JAGX

JAGX Key Data

Open

$1.11

 Day Range

1.07 - 1.13

52 Week Range

1.00 - 33.25

 Market Cap

$4.22M

Shares Outstanding

3.74M

 Public Float

2.23M

Beta

-0.10

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$33.98

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

378.77K

  

JAGX Performance

1 Week
 
 -6.84%
 
1 Month
 
 -19.26%
 
3 Months
 
 -49.30%
 
1 Year
 
 -95.77%
 
5 Years
 
 -100.00%
 

JAGX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About jaguar health inc - JAGX

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

JAGX At a Glance

Jaguar Health, Inc.
200 Pine Street
San Francisco, California 94104
Phone 1-415-371-8300 Revenue 11.69M
Industry Pharmaceuticals: Major Net Income -38,492,000.00
Sector Health Technology 2024 Sales Growth 19.752%
Fiscal Year-end 12 / 2025 Employees 49
View SEC Filings

JAGX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.636
Price to Book Ratio 1.832
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.322
Enterprise Value to Sales 3.221
Total Debt to Enterprise Value 0.97

JAGX Efficiency

Revenue/Employee 238,551.02
Income Per Employee -785,551.02
Receivables Turnover 7.097
Total Asset Turnover 0.224

JAGX Liquidity

Current Ratio 1.634
Quick Ratio 1.109
Cash Ratio 0.406

JAGX Profitability

Gross Margin 63.102
Operating Margin -263.761
Pretax Margin -335.794
Net Margin -329.301
Return on Assets -73.89
Return on Equity -522.599
Return on Total Capital -83.143
Return on Invested Capital -108.736

JAGX Capital Structure

Total Debt to Total Equity 373.859
Total Debt to Total Capital 78.897
Total Debt to Total Assets 68.369
Long-Term Debt to Equity 332.038
Long-Term Debt to Total Capital 52.249
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Jaguar Health Inc - JAGX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
4.33M 11.96M 9.76M 11.69M
Sales Growth
-53.81% +175.80% -18.36% +19.75%
Cost of Goods Sold (COGS) incl D&A
2.33M 4.31M 4.42M 4.31M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.83M 2.29M 2.39M 2.36M
Depreciation
127.00K 482.00K 436.00K 506.00K
Amortization of Intangibles
1.70M 1.81M 1.95M 1.85M
COGS Growth
-28.87% +84.78% +2.64% -2.53%
Gross Income
2.00M 7.64M 5.34M 7.38M
Gross Income Growth
-67.21% +281.87% -30.20% +38.23%
Gross Profit Margin
+46.18% +63.94% +54.67% +63.10%
2021 2022 2023 2024 5-year trend
SG&A Expense
41.08M 42.06M 39.26M 38.21M
Research & Development
15.08M 17.65M 18.60M 16.54M
Other SG&A
26.00M 24.41M 20.66M 21.66M
SGA Growth
+49.86% +2.40% -6.67% -2.67%
Other Operating Expense
- - - 1.63M
-
Unusual Expense
2.71M 2.21M 1.80M 8.24M
EBIT after Unusual Expense
(43.41M) (36.62M) (35.72M) (39.07M)
Non Operating Income/Expense
(765.00K) 950.00K 200.00K 51.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
8.42M 12.72M 6.38M 231.00K
Interest Expense Growth
+201.61% +51.09% -49.84% -96.38%
Gross Interest Expense
8.42M 12.72M 6.38M 231.00K
Interest Capitalized
- - - -
-
Pretax Income
(52.60M) (48.40M) (41.90M) (39.25M)
Pretax Income Growth
-55.58% +7.99% +13.42% +6.32%
Pretax Margin
-1,213.38% -404.78% -429.27% -335.79%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(52.60M) (48.40M) (41.90M) (39.25M)
Minority Interest Expense
(5.00K) (941.00K) (601.00K) (759.00K)
Net Income
(52.59M) (47.45M) (41.30M) (38.49M)
Net Income Growth
-55.57% +9.77% +12.97% +6.80%
Net Margin Growth
-1,213.26% -396.91% -423.11% -329.30%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(52.59M) (47.45M) (41.30M) (38.49M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(52.59M) (47.45M) (41.30M) (38.49M)
EPS (Basic)
-88.224 -36.1815 -1.7903 -5.2275
EPS (Basic) Growth
+60.79% +58.99% +95.05% -191.99%
Basic Shares Outstanding
596.15K 1.31M 23.07M 7.36M
EPS (Diluted)
-88.224 -36.1815 -1.7903 -5.2275
EPS (Diluted) Growth
+60.79% +58.99% +95.05% -191.99%
Diluted Shares Outstanding
596.15K 1.31M 23.07M 7.36M
EBITDA
(38.88M) (32.12M) (31.53M) (28.47M)
EBITDA Growth
-59.56% +17.38% +1.84% +9.70%
EBITDA Margin
-896.91% -268.68% -323.04% -243.59%

Snapshot

Average Recommendation BUY Average Target Price 35.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate -10.11
Last Quarter’s Earnings -6.28 Median PE on CY Estimate N/A
Year Ago Earnings -130.75 Next Fiscal Year Estimate -0.57
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A 1 1
Mean Estimate N/A N/A -10.11 -0.57
High Estimates N/A N/A -10.11 -0.57
Low Estimate N/A N/A -10.11 -0.57
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Jaguar Health Inc - JAGX

Date Name Shares Transaction Value
May 21, 2025 Lisa A. Conte CEO and President; Director 666 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Lisa A. Conte CEO and President; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Steven R. King See Remarks 145 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Steven R. King See Remarks N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 James J. Bochnowski Director 27,002 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 James J. Bochnowski Director 27,002 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 John J. Micek Director 9,000 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 John J. Micek Director 9,000 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 Jonathan Blair Siegel Director 9,000 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 Jonathan Blair Siegel Director 9,000 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 Jonathan S. Wolin See Remarks 9,000 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 Jonathan S. Wolin See Remarks 9,000 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 Pravin Ramsewak Chaturvedi Chief Scientific Officer 3,600 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 Pravin Ramsewak Chaturvedi Chief Scientific Officer 3,600 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 Carol R. Lizak Chief Financial Officer 5,400 Open market or private purchase of non-derivative security 0.00
Apr 4, 2025 Carol R. Lizak Chief Financial Officer 5,400 Open market or private purchase of non-derivative security 0.00

Jaguar Health Inc in the News